MSH Capital Advisors LLC Takes $856,000 Position in Novo Nordisk A/S $NVO

MSH Capital Advisors LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,423 shares of the company’s stock, valued at approximately $856,000.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. True Wealth Design LLC boosted its stake in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $30,000. NewSquare Capital LLC grew its stake in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares in the last quarter. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $37,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NVO shares. Morgan Stanley reissued an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. HSBC restated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, CICC Research assumed coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $56.07.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Berenberg maintained its Buy rating on Novo Nordisk, reinforcing investor confidence in the company’s growth outlook and valuation support from a respected European bank. Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
• Positive Sentiment: IQVIA data show Wegovy oral-pill prescriptions hitting ~38,220 in week five post-launch, signaling strong early uptake for the new oral formulation and supporting near-term revenue momentum. Novo’s Wegovy pill tracks over 38,000 prescriptions in fifth week
• Positive Sentiment: Company update: Novo completed a Phase 3 study of oral semaglutide in youth diabetes care — a potential label expansion that could broaden the drug’s addressable market if approved. Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care
• Positive Sentiment: Legal/market protection: U.S. officials may act against Hims after its attempted sale of a compounded Wegovy copy, which could help defend Novo’s IP and commercial position. US could take action including fines against Hims after brief Wegovy copy launch
• Positive Sentiment: Product strategy: Novo plans to introduce Wegovy in vial presentations (and other device formats), a move to improve access, pricing flexibility and supply resiliency amid competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: Usage trend: A study finds many Wegovy pill users are new to GLP‑1s, suggesting the product is bringing first‑time patients into the class and expanding market demand. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Company expansion: Coverage on Novo’s broader global healthcare initiatives highlights long‑term growth avenues but is less likely to move near‑term sentiment. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Industry context: A CNBC piece on pharma’s “reset” around pricing and pipelines frames regulatory and pricing headwinds that apply across the sector. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive landscape: Analysis comparing Eli Lilly and Novo Nordisk underscores intense competition in a rapidly growing weight‑loss market; investors should watch share trends and margin pressure. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market
• Negative Sentiment: Regulatory/legal risk: Coverage about FDA warnings and potential lawsuits tied to Wegovy highlights an ongoing downside risk to valuation if safety signals or litigation escalate. FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story

Novo Nordisk A/S Stock Up 1.4%

NVO stock opened at $49.59 on Friday. The stock has a market capitalization of $221.43 billion, a price-to-earnings ratio of 14.29 and a beta of 0.67. The company has a 50-day moving average of $53.74 and a two-hundred day moving average of $53.23. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.